ORIC — ORIC Pharmaceuticals Share News
0.000.00%
Last trade - 00:00ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows
Brief: ORIC Pharmaceuticals Q4 Net Income USD -30.505 Million
ORIC Pharmaceuticals Q3 net loss narrows to $32.6 mln
Brief: ORIC Pharmaceuticals Q3 Net Income USD -32.587 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: ORIC Pharmaceuticals Taps Kevin Brodbeck As Chief Technical Officer
Oric Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: ORIC Pharmaceuticals Q2 Net Income USD -36.355 Million
Oric Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
U.S. STOCKS ON THE MOVE-Bath & Body Works, Talkspace, EXP World
U.S. STOCKS ON THE MOVE-Nordson, copper miners, Boeing
U.S. STOCKS ON THE MOVE- Kohl's, Best Buy, NextDecade
U.S. STOCKS ON THE MOVE-Elf Beauty, US chipmakers, energy companies
ORIC Pharma jumps on promising data from prostate cancer drug trial